对抗SARS-CoV-2变种的双对应mRNA疫苗的有效性令人担忧
Monika Kumari1, Shih-Chieh Su1, Kang-Hao Liang2
1Institute of Cellular and Organismic Biology, Academia Sinica, No. 128, Academia Road, Section 2, Nankang, Taipei, 11529, Taiwan.
Journal of biomedical science
|June 28, 2023
概括
开发结合野生型 (WT) 和Omicron BA.5尖端mRNA的双价疫苗可以广泛保护SARS-CoV-2变种. 这一战略为未来的抗变体疫苗开发提供了一个有希望的方法.
科学领域:
- 病毒学 病毒学
- 疫苗学 疫苗学 疫苗学
- 分子生物学分子生物学
背景情况:
- 与SARS-CoV-2变种 (阿尔法,三角形,欧米克朗) 连续感染会导致显著的发病率.
- 尖蛋白中的突变会影响病毒传播和疫苗的疗效.
- 需要针对野生型 (WT) SARS-CoV-2及其变种有效的疫苗.
研究的目的:
- 设计和评估针对SARS-CoV-2 WT和变种的mRNA疫苗.
- 评估单价和双价mRNA-脂质纳米粒子疫苗的中和潜力.
- 为了确定最佳的mRNA组合,以提供广泛的变异保护.
主要方法:
- 为WT,Alpha,Delta和BA.5变种设计的全长尖峰mRNA.
- 配制的单价和双价mRNA-脂质纳米粒子疫苗.
- 使用免疫小鼠血清进行伪病毒中和测定.
主要成果:
- 单价疫苗显示出特定类型的疗效,除了BA.5,它中和了BF.7和BQ.1.1.1.
- 双等效疫苗 (例如,BA.5+WT,BA.5+Alpha,BA.5+Delta) 在很大程度上中和了多种变种 (WT,Alpha,Delta,BA.5,BF.7).
- BA.5+WT组合表现出对大多数令人担忧的变体 (VOC) 的高度中和.
结论:
- 结合两个mRNA序列是开发广泛保护SARS-CoV-2疫苗的有效方法.
- 确定了一个最佳的组合疗法,以增强变体中和.
- 提出了一项应对未来SARS-CoV-2变种引起关注的战略.
相关概念视频
Conjugated Proteins
18.4K
Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
18.4K
Cross-reactivity
31.3K
Overview
31.3K


